[클리니컬 히스토리] 지아이이노 GI-102, 키트루다 직접비교 승부수

GI Innovation's GI-102 has launched a head-to-head Phase 2 trial against Keytruda, marking a strategic shift from early exploration to direct commercial validation in the first-line melanoma market. This clinical milestone is vital for proving GI-102’s potential as a backbone therapy for various combinations, which is the primary driver for the company's future global licensing deals and financial stability.